Richard W Joseph

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma
    Richard W Joseph
    Department of Melanoma Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Immunother 35:66-72. 2012
  2. pmc Therapy for metastatic melanoma: the past, present, and future
    Laura Finn
    Division of Hematology and Oncology, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    BMC Med 10:23. 2012
  3. pmc NRAS mutation status is an independent prognostic factor in metastatic melanoma
    John A Jakob
    Department of Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 118:4014-23. 2012
  4. doi request reprint A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma
    Kevin B Kim
    Department of Melanoma Medical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, Texas 77030, USA
    Melanoma Res 22:294-301. 2012
  5. doi request reprint Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2
    Richard W Joseph
    Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    J Immunother 35:711-5. 2012
  6. pmc Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy
    Richard W Joseph
    Department of Melanoma Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 17:4882-91. 2011

Collaborators

Detail Information

Publications6

  1. pmc Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma
    Richard W Joseph
    Department of Melanoma Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Immunother 35:66-72. 2012
    ..56 vs. 1.97 y, P<0.0001), and trended toward a decreased response rate (7% vs. 21%, P=0.08). NRAS mutational status is a new candidate biomarkers for selecting patients with melanoma for HD IL-2 treatment...
  2. pmc Therapy for metastatic melanoma: the past, present, and future
    Laura Finn
    Division of Hematology and Oncology, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    BMC Med 10:23. 2012
    ..In this review we will discuss the advantages and limitations of the two new approved agents, current clinical trials designed to overcome these limitations, and future clinical trials that we feel hold the most promise...
  3. pmc NRAS mutation status is an independent prognostic factor in metastatic melanoma
    John A Jakob
    Department of Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 118:4014-23. 2012
    ....
  4. doi request reprint A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma
    Kevin B Kim
    Department of Melanoma Medical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, Texas 77030, USA
    Melanoma Res 22:294-301. 2012
    ..05). Cilengitide was well tolerated by patients in both the treatment arms but had minimal clinical efficacy as a single-agent therapy for metastatic melanoma, and the efficacy was not related to baseline αvβ3 expression...
  5. doi request reprint Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2
    Richard W Joseph
    Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    J Immunother 35:711-5. 2012
    ..Prospective trials of HD IL-2 followed by ipilimumab could potentially identify patients most likely to benefit from a sequential approach of HD IL-2 followed by ipilimumab...
  6. pmc Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy
    Richard W Joseph
    Department of Melanoma Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 17:4882-91. 2011
    ..However, little is known how clinical and pathologic features impact TIL outgrowth isolated from metastatic melanoma tumors...